

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

GRANT OF WAIVER UNDER RULE 19.41(A) OF THE GEM LISTING RULES AND DELAY IN DESPATCH OF THE CIRCULAR IN RESPECT OF MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE ISSUED SHARE CAPITAL IN PHC MEDICAL DIAGNOSTIC CENTRE LIMITED AND PREMIER MEDICARE SERVICES LIMITED

Reference is made to the announcements of China Biotech Services Holdings Limited (the “**Company**”) dated 18 May 2026 and 2 June 2026 respectively (the “**Announcements**”) in relation to, among others, the Disposal. Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Announcements.

DELAY IN DESPATCH OF THE CIRCULAR

As disclosed in the Announcements, a circular (the “**Circular**”) containing, among other information, (i) details of the Sale and Purchase Agreement, the Disposal and the transactions contemplated respectively thereunder; and (ii) other information as required under the GEM Listing Rules was expected to be despatched to the Shareholders on or before Tuesday, 9 June 2026 for their information only.

As more time is required for, among other things, finalising certain information for inclusion in the Circular, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with Rule 19.41(a) of the GEM Listing Rules on the condition that the Circular would be despatched on or before Friday, 26 June 2026.

By Order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 9 June 2026

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.